Current Chemotherapy News and Events | Page 25

Current Chemotherapy News and Events, Chemotherapy News Articles.
Sort By: Most Relevant | Most Viewed
Page 25 of 25 | 1000 Results
EORTC-ETOP study opens on pembrolizumab for patients with early stage NSCLC cancer
There is a need to improve treatment for this disease, and the EORTC in collaboration with European Thoracic Oncology Platform and with the sponsorship of MSD (known as Merck in the US and Canada) has now opened EORTC-ETOP trial 1416 to investigate the use of pembrolizumab in patients with early stage non-small cell lung cancer after resection and completion of standard adjuvant therapy. (2015-12-14)

Delaying chemotherapy in breast cancer patients reduces overall survival, especially for those with triple-negative breast cancer
Postponing the start of adjuvant chemotherapy for more than 90 days following surgery may significantly increase risk of death for breast cancer patients, particularly those with triple-negative breast cancer, according to a new study from the University of Texas MD Anderson Cancer Center. (2015-12-10)

Survival and time to surgery, chemotherapy for patients with breast cancer
The association between survival and the time to surgery and chemotherapy for patients with breast cancer is examined in two original investigations published by JAMA Oncology, along with a related editorial and an audio interview with the authors. (2015-12-10)

Nanotech drug delivery shows promise for improved melanoma treatment
Researchers have developed a new three-drug delivery system for cancer treatment, especially metastatic melanoma, the deadliest form of skin cancer -- and shown that the system may have particular value with cancers like this that often spread through the lymphatic system. It may offer a novel therapeutic option for more effective cancer treatment. (2015-12-09)

Women with luminal A subtype of breast cancer did not benefit from adjuvant chemotherapy
Premenopausal women whose invasive breast cancers were of the luminal A subtype had comparable 10-year disease-free survival rates regardless of whether or not they received adjuvant chemotherapy, according to data from the phase III DBCG77B clinical trial presented at the 2015 San Antonio Breast Cancer Symposium, held Dec. 8-12. (2015-12-09)

Drugs prevent heart damage during breast cancer treatment, study shows
Clinical trial shows heart medications prevent damage during chemotherapy for patients with breast cancer. (2015-12-09)

Experimental drug is first targeted therapy to improve survival in high-risk AML patients
Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia, reported Dr. Richard Stone, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology Annual Meeting and Exposition in Orlando. (2015-12-07)

Cancer study identifies genes that stop onset of leukemia
Genes that act as brakes to stop the development of an aggressive form of leukemia have been identified by University of Edinburgh researchers. Their findings offer fresh insights into how to tackle the disease and could lead to new therapies that prevent relapses. (2015-12-07)

Young adults with ALL have encouraging survival with pediatric regimen
Using a pediatric chemotherapy regimen to treat young adults with acute lymphoblastic leukemia (ALL) significantly improved their outcomes compared to what has historically been achieved with 'adult' treatment protocols, report Dana-Farber Cancer Institute scientists. (2015-12-07)

Experimental drug is first targeted therapy to improve survival in high-risk AML patients
Midostaurin added to standard chemotherapy is the first targeted treatment to improve survival of a high-risk, genetically defined subgroup of patients with acute myeloid leukemia, reported Dr. Richard Stone, of Dana-Farber Cancer Institute, on behalf of the Alliance for Clinical Trials in Oncology group, in a plenary session at the 57th American Society of Hematology Annual Meeting and Exposition in Orlando. (2015-12-07)

Multiple myeloma patient study shows promise for natural killer cells
A first-in-human Phase I study of multiple myeloma patients combined expanded cord blood-derived natural killer cells with transplantation of a patient's own stem cells and high-dose chemotherapy with little or none of the side effects seen with current treatments. (2015-12-07)

Clinical trial results show new drug is better for CLL patients
Older adults with chronic lymphocytic leukemia may have an alternative to toxic chemotherapy as their first treatment, according to a national study to be reported online Dec. 6, 2015, in the New England Journal of Medicine and co-authored by a Wilmot Cancer Institute oncologist. (2015-12-06)

Guided ultrasound plus nanoparticle chemotherapy cures tumors in mice
Thermal ablation with magnetic resonance-guided focused ultrasound surgery (MRgFUS) is a noninvasive technique for treating fibroids and cancer. New research from UC Davis shows that combining the technique with chemotherapy can allow complete destruction of tumors in mice. (2015-12-04)

Neurotoxic effects of chemotherapies on cognition in breast cancer survivors
Cancer-related cognitive impairment is often referred to as 'chemobrain' and anthracycline-based chemotherapy may have greater negative effects on particular cognitive domains and brain network connections than nonanthracycline-based regimens, according to an article published online by JAMA Oncology. (2015-12-03)

Genetic mutations differ within a single tumor, study finds
When researchers looked at different areas within an individual rectal cancer sample, they found cases in which each area contained different genetic mutations. The findings could have significant implications for treatment recommendations. (2015-12-02)

Stopping ovarian cancer in its tracks: An antibody may help patients heal themselves
In a first, Kyoto University shows the potential a PD-1 antibody, nivolumab, has in fighting the disease. (2015-12-01)

Chemotherapy can cause tumor evolution
Russian scientists have found that neoadjuvant chemotherapy in patients with breast cancer can stimulate evolution of the tumor. The results of the research conducted by Nicholay Litvyakov, D.Sc. at Cancer Research Institute, Head of the Tumor Virology Laboratory, and TSU researcher Marina Ibragimova, were published in 'Siberian Journal of Oncology.' (2015-12-01)

Black women less likely to benefit from early chemotherapy, study shows
A Yale Cancer Center study published recently in the Journal of Clinical Oncology found that among minority women treated with early chemotherapy, black women fare worse than the other groups. (2015-11-30)

New study on complete response rates for late-stage cancer
The report, 'Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates' by colleagues at Melbourne and Adelaide universities, has passed peer review on F1000Research. (2015-11-25)

Netupitant/palonosetron for prevention of nausea and vomiting: Added benefit not proven
There are certain advantages in side effects, but equivalence of the main effect, the prevention of nausea and vomiting in chemotherapy, has not been proven. (2015-11-23)

Investigational immunotherapeutic increased bladder cancer survival
Among patients with metastatic bladder cancer that had progressed after platinum-based chemotherapy, those who received an investigational, personalized peptide cancer vaccine and best-supportive care had extended overall survival compared with those who received best-supportive care alone, according to results from a randomized, phase II clinical. (2015-11-18)

Will immunotherapy add value to chemotherapy for HER-2 positive gastric cancer?
EORTC trial 1203 -- Integration of trastuzumab, with or without pertuzumab, into perioperative chemotherapy of HER-2 positive stomach cancer, is open for recruitment for patients with early, HER-2 positive gastric cancer. This phase II, randomized EORTC study was developed to investigate the added value of a perioperative treatment regimen which includes HER-2 targeting drugs for patients with gastric and gastro-esophageal junction cancers. (2015-11-13)

Personalized anti-nausea therapy better for cancer patients, Ottawa researchers
World-first trial published in JAMA-Oncology shows younger patients, women, those with history of either pregnancy-associated morning sickness or travel sickness, lower alcohol consumption, at greater risk of nausea and vomiting (2015-11-12)

Study reveals why chemotherapy may be compromised in patients with pancreatic cancer
A study at The University of Texas MD Anderson Cancer Center may explain why chemotherapy drugs such as gemcitabine are not effective for many pancreatic cancer patients, and perhaps point to new approaches to treatment including enhancing gemcitabine's ability to stop tumor growth. (2015-11-11)

Drug protects fertility and may prolong life in chemo-treated mice
A University of Wisconsin-Madison physician and her research team have shown that a heart medication can prevent ovarian damage and improve survival in adolescent mice after chemotherapy. The treatment also increased the number of their healthy offspring. (2015-11-06)

DNA strands often 'wiggle' as part of genetic repair
New research indicates that every time a double-stranded break occurs in DNA strands, the damaged ends move about during repair. Scientists believe that a better understanding of this mysterious mechanism could improve the use of cancer treatments, some of which manipulate DNA repair in malignant cells. (2015-11-05)

CK5 marks cisplatin-resistant ovarian cancer
A University of Colorado Cancer Center study recently published in the International Journal of Gynecological Cancer shows that protein cytokeratin 5 (CK5), known to be a marker of poor prognosis in breast cancer, also marks ovarian cancers likely to be resistant to the common chemotherapy cisplatin. (2015-11-04)

Study rejects biologic age as limiting factor for stem cell transplants
More than 40 percent of older patients with acute myeloid leukemia (AML) can remain in long-term cancer remission through a modified, less aggressive approach to donor stem cell transplantation, according to the results of a phase 2 study led by oncologists at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC -- James). (2015-11-04)

Chemotherapy-induced hearing loss affects cognition in pediatric brain tumor survivors
More children are surviving malignant brain tumors than in the past, thanks to the use of intense treatments using platinum-based chemotherapy (cisplatin and high-dose carboplatin). Unfortunately, the therapy has a known side effect of permanent hearing loss, resulting from damage to the inner ear. Investigators at Children's Hospital Los Angeles now report that this type of chemotherapy may not only impact hearing, but that the hearing loss may then contribute to long-term neurocognitive deficits. (2015-11-03)

Simple test predicts response to chemotherapy in lung cancer patients
Scientists at Lawson Health Research Institute have found that adenocarcinoma patients who undergo chemotherapy and surgery experience significantly improved survival rates when their tumor is lacking the retinoblastoma tumor suppressor protein. This new information is very useful as it may predict which patients will respond best to chemotherapy. (2015-11-03)

Study: Only 1 in 5 US pancreatic cancer patients get this key blood test at diagnosis
Only one in five US pancreatic cancer patients receive a widely available, inexpensive blood test at diagnosis that can help predict whether they are likely to have a better or worse outcome than average and guide treatment accordingly, a Mayo Clinic study shows. (2015-11-03)

UGA researchers discover mechanism that could lead to better ovarian cancer treatment
Resistance to chemotherapy is a major problem for those suffering from ovarian cancer -- a problem that prevents a cure from a disease dubbed the 'silent killer.' University of Georgia researchers are giving patients new hope with recent findings that help pinpoint the mechanisms causing chemoresistance. (2015-10-26)

WSU researchers develop natural protein cage for improved cancer drug delivery
Washington State University researchers have developed a unique, tiny protein cage to deliver nasty chemotherapy chemicals directly to cancer cells. Direct delivery could improve treatment and lessen what can be horrendous side effects from toxic drugs. (2015-10-26)

FDA approves new therapy for pancreatic cancer patients
Patients with advanced pancreatic cancer now have access to the new FDA approved drug, Onivyde, that produced significant overall survival rates in an international clinical study conducted in part by researchers at HonorHealth Research Institute and the Translational Genomics Research Institute. (2015-10-26)

Biologists unravel drug-resistance mechanism in tumor cells
MIT cancer biologists have discovered that Targeting the RNA-binding protein that promotes drug-resistance could lead to better cancer therapies. (2015-10-22)

For lung cancer patients, IMRT associated with lesser side effects, better tolerance of chemotherapy, compared to conventional radiation therapy
An analysis of an international, cooperative-led trial of patients with locally advanced non-small cell lung cancer has shown that those who received intensity modulated radiation therapy had less severe lung toxicity and were able to better tolerate their chemotherapy, compared to patients who received 3-D conformal radiation therapy. (2015-10-18)

New test to predict relapse of testicular cancers
Scientists have developed a new test to identify patients who are at risk of suffering a relapse from testicular cancer. Assessing just three features of a common kind of testicular cancer -- called non-seminomatous germ cell tumor -- can identify those at most at risk of relapse even where there is no evidence of tumor spread. The researchers believe the test could be used in the clinic to make decisions about which patients should be given chemotherapy. (2015-10-15)

The Lancet Infectious Diseases: Study quantifies threat of rising antibiotic resistance on surgery and chemotherapy
Researchers report the strongest evidence yet that rising antibiotic resistance could have disastrous consequences for patients undergoing surgery or cancer chemotherapy. New estimates published in The Lancet Infectious Diseases journal suggest that up to half of infections after surgery and over a quarter of infections after chemotherapy are caused by organisms already resistant to standard prophylactic antibiotics in the USA. (2015-10-15)

CWRU researcher lands grant to build stealthy brain tumor treatment
A Case Western Reserve University researcher has received a five-year, $2.82 million National Institutes of Health grant to make chain-like nanoparticles that can carry drugs across the blood-brain barrier to treat glioblastoma multiforme. The nanochains will carry traditional chemotherapy and glioblastoma stem cell inhibitors to destroy the tumor and eliminate cancer cells that are resistant. (2015-10-14)

Preclinical study shows potential to increase the effectiveness of leukemia treatments
Preclinical experiments led by a team of researchers at VCU Massey Cancer Center have shown that blocking the production of a protein known as chromodomain helicase DNA-binding protein 4 may help increase the effectiveness of first-line treatments for acute myeloid leukemia, a particularly lethal blood cancer that is increasing in incidence among older adults. (2015-10-13)

Page 25 of 25 | 1000 Results
   First   Previous   Next      Last is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to